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The association of the non-AIDS-related, classic fonn of
Kaposi's sarcoma (KS) with secondary malignancies,
especially Iymphoproliferative disorders, has frequently
been noted. However, in endemic:< African-type KS, such
an association has been reported only rarely. A review of
62 non-AiDS-related cases of KS treated and followed up
at Johannesburg General Hospital between 1980 and 1992
revealed 8 patients (13%)'in whom KS was associated
with malignant Iymphoproliferative disorders. The
prevalence of secondary Iymphoproliferative disorders
was not significantly different among patients with classic
KS (3/15; 20%) when compared with those who had
African KS (4/47; 8%). In both fonns of KS subtle
disturbances of imml,Jnity have been described which may
play a role in the pathogenesis of secondary
Iymphoproliferative disorders, although the factors
responsible and the pathogenetic mechanisms involved in
malignant lymphoid transfonnation in these patients have
not been fully elucidated.






An association between the classic type of KS and
Iymphoproliferative disorders has been reported with a
frequency ranging between 17% and 60%.3 The Iympho-
proliferative disorders are mostly of B-cell origin and include
non-Hodgkin's lymphoma, chronic lymphatic leukaemia and
multiple myeloma.'·5 An association with lymphoid disorders
of undefined status, but which may be premalignant, such
as Castleman's disease (angiofollicular lymph node
hyperplasia) and angio-immunoblastic lymphadenopathy,
has also been described."·7 Impaired immune function
appears to be the underlying factor predisposing to either
KS, Iymphoproliferative disorders or both."
While classic KS is frequently associated with
Iymphoproliferative disorders, only a few instances of an
association between the endemic, African-type of KS and
other malignancies have been reported.9-" The scarcity of
reported cases may be due to short follow-up of non-
compliant patients, lack of appropriate medical facilitj~s in
many underdeveloped countries and shorter survival due to
accompanying infectious events."·12
In this retrospective analysis, 8 patients with non-AIl:>S-
associated KS and Iymphoproliferative disorders are
reported. The current literature is reviewed.
Patients and methods
The records of all patients with non-AIDS-related KS
(negative HIV enzyme-linked immunosorbent assay (EL/SA),
no history of opportunistic infection), treated at
Johannesburg General Hospital from 1980 to 1992, were
reviewed. All patients underwent physical examination,
haematological and biochemical studies and chest
.radiography. Where clinically appropriate, gastro-intestinal
radiography or endoscopy, abdominal sonography or
computed tomography was performed. Tumour stage was
established according to the Mitsuyasu classification
system.'3 Patients were treated with various radio;- and
chemotherapeutic regimens.
-
Non-AIDS-associated Kaposi's sarcoma (KS) is a rare
vascular tumour, affecting mainly the skin but also involving
regional lymph nodes and internal organs. The disease has a
high incidence among Jews of eastern European descent'
and is the most common neoplastic disease in the sub-
Saharan black population.2
Department of Medical Oncology and Haematology,
Johannesburg Hospital
M. E. Stein. M.D.
D. Spencer. EG.P. (SA)
R. Dansey. EG.P. (SA)
W. R. Bezwoda. PHD.
Department of Pathology, South African Institute for Medical
Research, Johannesburg
Y. Perner. EG.PATH. (SA) .
Department of laboratory Haematology, University of the
Witwatersrand, Johannesburg
K. Gunther. EG.PATH. (SA)
Results
Classic KS
There were 15 patients with the classic fonn of KS. Ten
(67%) were male and 5 (33%) were female. The age at
diagnosis of KS ranged from 26 to 81 years with a mean age
of 70 years. The majority (7-1 %) of the patients were Jews of
eastern European descent. One patient was Italian born and
the rest were white South Africans.
Six patients (40%) 'had stage I disease (KS limited to one
anatomical region), 6 patients stage 11 disease (multiple skin
lesions) and 3 patients (20%) presented with stage IV
disease (disseminated skin lesions, lymphadenopathy and/or
involvement of the gastro-intestinal tract).
Associated Iymphoproliferative disorders (Table I)
Three patients had a diagnosis of Iymphoproliferative
disorders preceding the diagnosis of KS. One patient had a
6-year history of Waldenstrom's macroglobulinaemia before
presenting with KS of the lower limbs. This patient had
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asymptomatic biclonal IGM (kappa) paraproteinaemia, low
IgA titre, Bence Jones proteinuria and mild renal
dysfunction. One patient developed KS 3 years after the
diagnosis of stage IVB Hodgkin's disease. This patient had
been treated with various chemotherapeutic regimens for
the lymphoma. Complete remission was never achieved and
he died of progressive Hodgkin's disease 3 years after
diagnosis with minimal evidence of KS. The third patient de-
veloped KS of the right thigh 2 years after the diagnosis of a
follicular low-grade stage IV non-Hodgkin's lymphoma. This
patient was not treated initially either for the lymphoma or
the KS but 3 years later, following progression of the
lymphoma, she received chlorambucil and prednisone and
achieved near-complete remission both of the KS and the
malignant lymphoma.
One patient developed Castleman's disease 54 months
after the diagnosis of KS. The Castleman's disease involved
the mediastinal lymph nodes, adjacent pericardium and
pleura and the patient died of complications related to this
involvement with stable KS confined to the skin.




Forty-seven HIV-1-negative black men domiciled in the
southern African region, including South Africa,
Mozambique, Botswana, Namibia and Malawi were included
in this study. Their mean age was 53 years (range 24 - 82
years). Thirty-seven patients (80%) presented with disease
limited to skin only and 10 patients (20%) with extensive
disease involving the skin and gastro-intestinal tract as well
as lymphadenopathy and/or pulmonary involvemerlt.
Associated Iymphoproliferative disorders (Table 11)
Three patients had a non-Hodgkin's lymphoma (1 high-
grade, peripheral T-cell lymphoma; 1 low-grade follicular
non-Hodgkin's lymphoma; 1 large-cell immunoblastic
lymphoma) as well as KS. All the lymphomas were
diagnosed at the same time as the KS. The lymphoma was
limited to the peripheral lymph n'odes in each case and
responded significantly, though incompletely, to
chemotherapy. All three patients died of progressive KS.
A fourth patient presented with advanced KS, involving the
Lympho-
Stage Treatment proliferative
Patient no. Age/sex of KS of KS disorder
76/F 11 Interferon Waldenstr6m's
macroglo-
bulinaemia
2 65/M Radiation Hodgkin's
therapy disease
3 70/F Radiation Low-grade
therapy lymphoma
4 69/M Radiation Castleman's
therapy disease



























Table 11. Association of endemic, African KS with Iymphoproliferative disorders
Stage/ Lympho- Treatment pf
localisa- Treatment proliferative Iymphoprolifera-
Patient no. Age tion of KS of KS disorder Stage tive disorder Outcome
60 I; lower Radiation Low-grade Peripheral COPP Lymphoma
limbs therapy; lymphoma (well lymphadenopathy responded; died
local field; differentiated (stage I or of progressive
2400 cGy lymphocytic stage 11 disease) KS
lymphoma)
2 78 I; right Radiation High-grade, III peripheral COPP Regression of
leg therapy; peripheral mediastinal lymphoma; died
local fields; T-eell para-aortic of progressive KS
2400cGy lymphoma lymphadenopathy
3 34 IV; disseminated Vinblastine, Immunoblastic Lymphadenopathy CHOP Incomplete
skin lesions; etoposide; lymphoma (stage 11 or III response of
Iymphadeno- radiotherapy disease) lymphoma; died
pathy of progressive KS
4 23 IV; disseminated Diffuse IV (bone marrow Cytosar + Partial response;
skin and large cell involved) (?liver/ interferon; died following
peripheral lymphoma ?spleen) CHOP massive relapse
lymph node and neutropenic
involvement sepsis
All patients were male. coPP = cyclophosphamide, oncovin, prednisone, procarbazine.
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skin and peripheral lymph nodes (Figs 1 and 2) as well as
hepatosplenomegaly, ascites and pleural effusion. Immune
function tests showed an absolute T-cell lymphopenia with a
low T4fT8 ratio (0,78:1). Bone marrow trephine biopsy
revealed infiltration by B-celllymphoma (Figs 3 and 4). After
chemotherapy consisting of cytosar and interferon-alpha, a
partial reduction in tumour bulk was achieved together with
Fig. 1. Lymph node, including capsule, showing effacement
of normal nodal architecture as a result of KS (Iow power
magnification; H & E).
Fig. 2. KS with numerous slit-like spaces. Nuclear pleomorphism
and increased mitotic activity are readily discernible (10 x 40;
H&E).
marked symptomatic improvement. This patient was
continuing with the CHOP regimen (cyclophosphamide,
epidoxorubicin, oncovin, prednisone) with a very good initial
response. The patient, however, relapsed and died about 3
months after the start of CHOP therapy, with a rapidly
enlarging liver, pancytopenia and extensive bone marrow
involvement. Permission for autopsy was refused.
Fig. 3. Bony trabeculum with adjacent marrow cavity showing
diffuse, marked hypercellularity caused by involvement of non-
Hodgkin's lymphoma (Iow power magnification; H & E).
Fig. 4. Polymorphous infiltration of lymphoma cells of B-lineage
within the marrow cavity. Large binucleate cell identified in centre
of the field (10 x 40; H & E).
-
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Discussion
A close association between classic KS and secondary
malignancies was appreciated as early as 1954.",'4 In 1966
Moertel'5 reported KS appearing as a second primary cancer
in 51 of 565 patients with Iymphoreticular tumours - an
incidence of 9%. Other authors'6-'· found an association
between KS and lymphoma ranging between 6% and 14%.
Safai et al., '0 reviewing the Memorial Sloan Kettering Cancer
Center experience (1949 - 1975), found 92 patients with
classic KS, of whom 34 (37%) developed a second primary
malignancy. In these patients, the second malignancy
involved the Iymphoreticular system in 58%. By contrast,
only 8% of all patients with primary malignancies other than
KS developed lymphoid tumours as second malignancies.
In the light of tumour registry data from Connecticut and
New York,3 the age- and sex-adjusted rates for
Iymphoproliferative malignancies in KS patients was found
to be 20-fold greater than in the general population. In a
recent review, Friedman-Kien and co-workers20 found that
about one-third of patients with KS have a history of, or later
develop, malignancies of reticulo-endothelial origin,
including B-cell lymphoma, chronic lymphatic leukaemia,
multiple myeloma and thymoma.
Little is known about the pathogenesis of
Iymphoproliferative disorders in non-AIDS-related KS.
Moertel and Hagendrom21 even proposed a common
progenitor cell for KS and lymphoma. Recent studies of the
pathogenesis of KS make this unlikely.'3.22Zl More probable is
impaired immune surveillance and T-cell regulatory
dysfunction in patients with KS leading to unopposed
proliferation of abnormal B-cellsY.22 The aggressive course
of KS in immune-suppressed patients as well as the more
widespread and rapidly progressive form of epidemic, AIDS-
related KS, also suggest a significant role for impaired
immunity in the aetiology and pathogenesis of KS.20Zl
In addition, the prolonged use of chemotherapy,
particularly alkylating agents and immunosuppressive drugs,
has also been associated with an increased frequency and
more aggressive course of KS. Examples include the •
development of KS in patients who have undergone organ
transplants, patients with auto-immune diseases and
patients with thymoma. Total cumulative dose and length of
exposure appear to be important in determining the
frequency of malignancy in such patients.",24 In the present
study only 1 patient with classic .KS had received any
chemotherapy prior to diagnosis. The other 2 patients with
lymphoma had received no chemotherapy before the
diagnosis. Prolonged use of chemotherapy was thus unlikely
to be a major factor in our patients.
Of special interest with regard to the Iymphoproliferative
disorders associated with KS is the patient who developed
Castleman's disease (angiofollicular lymph node hyperplasia)
54 months after the diagnosis of KS. Castleman's disease is
characterised histologically by prominent vascular
proliferation, resembling that of KS: Chronic antigenic
stimulation is thought to result in Iymphoreticular and
endothelial cell proliferation which in turn lead to T-cell
regulatory dysfunction and excessive proliferation of B-cells.6,25
Castleman's disease resembles classic KS in respect of
immune function disturbances. Low natural killer cell activity,
cutaneous anergy, low suppressor T-cell activity and
increased levels of the Iymphokine, IL-6,".22,26 have been
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found in both conditions. Both KS and Castleman's disease
respond to radio- and chemotherapy and in both diseases
treatment results in partial restoration of immune responses
following regression of disease.27.28 However, while the
similarities between the two diseases are striking, less than
20 cases of Castleman's disease in association with KS
have been reported so far.6.25-30 The majority of the cases
were related to the multicentric angiofollicular lymph node
hyperplasia (plasma cell type) group which is a more
aggressive variant of Castleman's disease.6,29,30 This type of
Castleman's disease is associated with severe impairment of
immune regulation and transition to Iymphoproliferative
disorders or KS has been described.3'-33
With regard to the association of the African endemic form
of KS and second malignancy, early reports seemed to
suggest that African KS might also be associated with
increased risk of Iymphoproliferative disorders.9-'2 In 1962
Murray and Lothe34 described Hodgkin's disease in
association with KS. Uys and Bennet,35 McKinney"" and
Kungu and Gatej37 described sporadic cases of KS with
associated Iymphoproliferative disorders. However, in a
series of 117 cases of KS in Tanzania, only 1 patient had
Hodgkin's disease while in another series only 2 of 339
patients with African KS had lymphoma.·'"
Endemic African KS has generally not been considered to
be associated with severe immune deficiency.38 Recent
reports have, however, demonstrated alteration in cell-
mediated immunity and Iymphocyte function in the endemic
variant of KS.2-39 In Africa, the co-existence of malnutrition
and chronic infections such as malaria, chronic helminthic
infestations and hepatitis may also result in impaired cellular
immunity.23 The emergence of a very aggressive form of
African KS38 and the occurrence of KS in childhood8,13 with
its fulminant course, suggest that immune suppression may
also play a role in this variant of KS.40,4' It is possible that the
younger age of patients with African KS, as well as the
shorter survival of such patients compared with those with
classic KS, might be responsible for the lower frequency of
Iymphoproliferative disorders in African KS." Additional
reasons may be underreporting due to limited medical
facilities and lack of follow-up of such patients in the African
context!.38 However, in the current series 4 of 47 patients
(8%) with African KS had associated Iymphoproliferative
disorders, a prevalence not significantly different from that
seen among patients with classic KS (3/15, 20%). While
these figures are lower than those described by Safai and
co-workers,'o they appear to be more in keeping with the
prevalence found by other investigators.
While both forms of KS thus appear to be associated with
Iymphoproliferative disorders, it is necessary to ascertain
which influences which, since there is no consistency
regarding which illness occurs first. The association with
lymphoma may be due to a common pathogenetic
mechanism rather than a directly causal relationship. KS and
Burkitt's lymphoma have the same geographical distribution
and may be related to Epstein-Barr virus infection, which is
endemic in Africa.'o Other antigenic stimuli may also result in
chronic proliferative stimuli both to lymphoid and vascular
endothelial cells which, in the presence of immune
dysfunction, result in malignant transformation. This possibility
is suggested by the occurrence of as yet ill-defined entities,
such as Castleman's disease which appears to share a
number of features with both KS and Iymphoproliferative
SAMJ Volume 84 No. 8 August 1994
disorders and which has on occasion been associated with
the progressive development of one or other malignancy.
Further investigation of patients may well show the occurrence
of common pathogenetic mechanisms.
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The value of abrasive
cytology in the early
detection of oesophageal
carcinoma
A pilot survey in Ciskei
C. Lazarus, K. Jaskiewicz, H. A. Southall,
R. A. Sumeruk, J. Nainkin
The use of abrasive cytology as a screening procedure in
the diagnosis of early cancer of the oesophagus among
asymptomatic rural Ciskeians was assessed. An
inexpensive, locally man~factured brush biopsy caPSUle
was used to obtain cytological material from 1 336
subjects. The technique gives a high yield, has a high
predictive value and identifies a high prevalence of .
sufferers at the detectable preclinical phase of the
disease.
S Afr Med J 1994; 84: 488-490.
Squamous cancer of the oesophagus is the commonest
cancer among black men in southern Africa. Only cancer of
the cervix among black women is more prevalent.' It was
especially common among rural Transkeians,' but is now
also found increasingly in urban populations of the region!-6
As a rule, patients with oesophageal cancer present at an
advanced stage of relentless progression. While patients'
symptoms are usually of recent origin, their period of
survival is shortY This cancer therefore seems to fulfil many.
of the criteria necessary for it to be suitable for screening.
These include: (i) a high prevalence in a susceptible
population; (H) its recognition as a serious disease in the
community; (Hi) effectiveness of cancer therapy, either by
means of surgery or radiotherapy; and (iv) a well-
documented, prolonged 'detectable pre-c1inical phase'
(DPCP) when effective therapy could lead to a cure.~
Abrasive brush cytology as a screening technique for
oesophageal cancer has been used for many years in high-
incidence areas of China. Early diagnosis and many long-
term survivors have been reported.'O,l1 In southern Africa,
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